Gary Schiller, MD
Hematology & Oncology · Los Angeles, CANPI 1851311930
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $200,064 of the $253,662 with a category attached, or 78.9%. It is spread thinly across 34 manufacturers, the largest accounting for just 15.8%. Reporting peaked in 2019 at $66,096 and has fallen 63.3% since, to $24,285 in 2025. Among hematology & oncology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 230 payments — averaging $1102.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$40K
- Karyopharm Therapeutics Inc.$32K
- E.r. Squibb & Sons, L.L.C.$19K
- Gilead$18K
- Astellas Pharma US Inc$16K
- Rigel Pharmaceuticals, Inc.$16K
- plus $112K from 28 others
Across 812 payments — averaging $14,388 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$4.1M
- Jazz Pharmaceuticals Inc.$923K
- National Marrow Donor Program$823K
- AbbVie$793K
- Karyopharm Therapeutics Inc.$677K
- Amgen$598K
- plus $3.8M from 21 others
What the payments were for
- Consulting fees$40,65516%
- Speaking & faculty fees$200,06479%
- Travel & lodging$6,5843%
- Food & beverage$5,7922%
- Education$5670%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 24 | $40,128 |
| Karyopharm Therapeutics Inc. | 22 | $32,461 |
| E.r. Squibb & Sons, L.L.C. | 11 | $19,061 |
| Gilead(2 entities) | 14 | $18,053 |
| Astellas Pharma US Inc | 16 | $16,361 |
| Rigel Pharmaceuticals, Inc. | 13 | $15,910 |
| Agios Pharmaceuticals, Inc. | 13 | $14,590 |
| Stemline Therapeutics Inc. | 12 | $11,490 |
| Sanofi | 6 | $10,900 |
| Bristol Myers Squibb | 15 | $10,111 |
| Amgen | 9 | $9,179 |
| Geron Corporation | 3 | $6,797 |
| Novartis | 4 | $6,049 |
| Blueprint Medicines Corporation | 5 | $6,045 |
| AstraZeneca(2 entities) | 13 | $5,157 |
| Incyte Corporation | 6 | $4,591 |
| Johnson & Johnson | 10 | $4,547 |
| Pfizer | 5 | $4,188 |
| Autolus Inc | 3 | $3,744 |
| AbbVie | 4 | $3,635 |
| GSK | 2 | $3,150 |
| Gamida Cell Inc. | 3 | $2,533 |
| Innate Pharma, Inc | 1 | $2,400 |
| Genetix Biotherapeutics Inc | 2 | $1,332 |
| Taiho Oncology, Inc. | 3 | $323 |
| Eurofins Viracor, LLC | 1 | $283 |
| EUSA Pharma (US) LLC | 1 | $225 |
| Sanofi-aventis U.S. LLC | 3 | $207 |
| CTI Biopharma Corp. | 1 | $50 |
| Servier Pharmaceuticals LLC | 1 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $42 |
| Adaptive Biotechnologies Corporation | 1 | $31 |
| Apellis Pharmaceuticals, Inc. | 1 | $25 |
| Beone Medicines USA, Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$253,662 in reported general payments places this provider in the 95th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Imatinib Mesylate | 18 | $44,165 |
| Acyclovir | 16 | $181 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Los Angeles
- Dennis SlamonLos Angeles$3.1M
- George YaghmourLos Angeles$1.9M
- Kevin KellyLos Angeles$894K
- Raghuveer RanganathanLos Angeles$609K
- Matthew RettigLos Angeles$442K
- David BerzLos Angeles$420K
- Gottfried KonecnyLos Angeles$402K
- Antoni RibasLos Angeles$315K
- Edward GaronLos Angeles$301K
- Rahul NaikLos Angeles$297K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.